-+ 0.00%
-+ 0.00%
-+ 0.00%

Market Chatter: Novo Nordisk's Wegovy Gets Indian Regulator Nod to Treat Aggressive Fatty Liver Disease

MT Newswires·07/17/2026 09:31:53
Listen to the news
09:31 AM EDT, 07/17/2026 (MT Newswires) -- India's drug regulator approved Novo Nordisk's (NOVO-B.CO) Wegovy to treat metabolic dysfunction-associated steatohepatitis, Reuters reported on Friday. The Central Drugs Standard Control Organisation granted a 2.4 mg semaglutide injection of the drug to treat the aggressive form of fatty liver disease. Novo Nordisk did not immediately respond to a request for comment from MT Newswires. (Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)